<DOC>
	<DOCNO>NCT02741115</DOCNO>
	<brief_summary>This study evaluate clinical efficacy safety udenafil , orally administer , potent selective inhibitor PDE5 , versus placebo treatment adolescent subject undergone Fontan procedure .</brief_summary>
	<brief_title>Fontan Udenafil Exercise Longitudinal Assessment Trial</brief_title>
	<detailed_description>This study randomize , double-blinded , efficacy trial effect udenafil vs. placebo background standard therapy maximal VO2 ( ml/kg/min ) baseline six month adolescent survivor Fontan procedure . . The target sample size 400 subject ( 200 per group ) .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>1 . Males females Fontan physiology 12 less 19 year age enrollment . 2 . Participant consent parental/guardian consent participant assent 3 . Participant fluency primary language country study conduct 1 . Weight &lt; 40 kg 2 . Height &lt; 132 cm . 3 . Hospitalization acute decompensated heart failure within last 12 month . 4 . Current intravenous inotropic drug . 5 . Undergoing evaluation heart transplantation list transplantation . 6 . Diagnosis active protein lose enteropathy plastic bronchitis within last 3 year , history liver cirrhosis . 7 . Known Fontan baffle obstruction , branch pulmonary artery stenosis , pulmonary vein stenosis result mean gradient &gt; 4 mmHg region proximal distal obstruction measure either catheterization echocardiography , obtain prior screen trial . 8 . Single lung physiology great 80 % flow one lung . 9 . VO2 le 50 % 10 . Severe ventricular dysfunction assess qualitatively clinical echocardiography within six month prior enrollment . 11 . Severe valvar regurgitation , ventricular outflow obstruction , aortic arch obstruction assess clinical echocardiography within six month prior enrollment . 12 . Significant renal ( serum creatinine &gt; 2.0 ) , hepatic ( serum AST and/or ALT &gt; 3 time upper limit normal ) , gastrointestinal biliary disorder could impair absorption , metabolism excretion orally administer medication , base laboratory assessment six week prior screen trial . 13 . Inability complete exercise test baseline screening . 14 . History PDE5 inhibitor use within 3 month study onset . 15 . History medication treatment pulmonary hypertension within 3 month study onset . 16 . Known intolerance oral udenafil . 17 . Frequent use medication substance inhibit induce CYP3A4 . 18 . Current use alphablockers nitrate . 19 . Ongoing plan participation another research protocol would either prevent successful completion plan study test invalidate result . 20 . Noncardiac medical , psychiatric , and/or social disorder would prevent successful completion plan study test would invalidate result . 21 . Cardiac care , ongoing plan , nonstudy center would impede study completion . 22 . For female : Pregnancy time screening , pregnancy plan study completion , refusal use acceptable method contraception study duration sexually active . 23 . Unable abstain limit intake grapefruit juice duration trial . 24 . Refusal provide write informed consent/assent . 25 . In opinion primary care physician , subject likely noncompliant study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fontan</keyword>
	<keyword>Maximal Oxygen Consumption</keyword>
	<keyword>Vascular Function</keyword>
	<keyword>EndoPAT</keyword>
	<keyword>Myocardial Performance</keyword>
</DOC>